Navigation Links
Compound from cottonseed for neck and head cancers

A chemical compound derived from the cottonseed oil had showed promise in treating the cancer of head and neck.//

Scientist from University of Michigan Comprehensive Cancer Center had found that the chemical compound called gossypol regulates the protein called Bcl-xL, which is found over-expressed in the cancer cells that are found in the head or neck.

Head and neck cancers are difficult to treat as they are resistant to chemotherapy. Surgeries on such cases have proved to affect the ability of the patient to talk, swallow or breathe.

The newly effective compound from the cottonseed oil has been able to kill carcinogenic cells to a success rate of 70% to 90%. The treated cell cultures of head and neck squamous cell carcinoma with gossypol compound have also been seen to inhibit the growth of tumors.

This new treatment may be like a boon to patients suffering from cancer of head or neck, as there was no previous treatment available that did not cause them any long-term complaints.

The results of the study were published in the journal Clinical Cancer Research.
'"/>




Page: 1

Related medicine news :

1. Compound of Broccoli combats breast cancer
2. New Compound Could Strengthen The Effect Of Chemotherapy
3. Breathing Cancer Causing Compounds During Pregnancy Found To Affect Offspring
4. Compounds Found In The Vegetable Broccoli Could Have Anti-Cancer Properties
5. Adding Sorghum Compounds To Dietary Supplements May Help Lower Cholesterol
6. Compound In Grapes And Red Wine To Counter Alzheimers Disease
7. Sugars Could Contain Key Cancer Inhibiting Compounds
8. Compound From Cyanobacterium Can Fight Alzheimer’
9. Five New Anti-Inflammatory Compounds Produced By Indian Scientists
10. Compounds in Licorice Can Fight Tooth Decay
11. New Compound Offers Hope In Liver Cancer Treatment
Post Your Comments:
(Date:7/25/2008)... Authority offers patients consumers tips and enco...nt safety, HARRISBURG, Pa., July 25 /PRNewswire-U...ority today supports "National Patient Safety Day"...and their families to,participate fully in their h...ing they can about their surgery or illness., "We...
(Date:7/25/2008)... - 180-Days of Marketing Exclusivity Begin...l/ -- Watson,Pharmaceuticals, Inc. (NYSE: WPI ), ...ced today that its subsidiary has commenced commer...psules USP product in the 40mg,strength from its D...on,with the launch, Watson has 180 days of marketi...
(Date:7/25/2008)...ck to benefit ALS Therapy Alliance to be presented...ight, WOONSOCKET, R.I., July 25 /PRNewswire/ -- C...raised a record-breaking $4.4 million in just 21 d...gn for ALS research. This is,the seventh year of t...aised more than $15 million for ALS research. This...
(Date:7/25/2008)... The Retina Group of New York wi...lated macular degeneration especially designed for...ale Public Library at 116 Merritts Road, Farmingda...15. Attendance is free and refreshments will be pr...516) 939-6100. , Hicksvil...
Breaking Medicine News(10 mins):Health News:Patient Safety Authority Supports 'National Patient Safety Day' 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 3Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:CVS/pharmacy Raises Record-breaking $4.4 Million for ALS Research Through Annual ALS Fundraising Campaign 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 3
...ined that the deadly Human Immune Deficiency Virus...accine used in Africa in the 1950s and say rumours...ce to back them up. The studies, from researchers ...d help free the polio vaccine manufactured by the ...
... most painful and bothering one is the trauma of g... according to many diabetics is the finger stick. ...p to six times a day for more than ten to twenty y...he pain and discomfort associated with them. But r...
...hursday that plans are afoot to consider listing o...n the US bourses after 2002," Pratap C Reddy, chai... was a part of the business plan for the post-2002...available at the moment, Dr. Reddy added that plan...
... can be prevented if the patients and their doctor...ng to WHO, around 150 million people suffer from a...o the disease every year. Asthma is a chronic resp...t is characterized by sudden recurring attacks of ...
Other Medicine News:
(Date:7/24/2008)...-FirstCall/ -- Alexza,Pharmaceuticals, Inc. (Nasda...ts second Phase 3 clinical trial with AZ-004 (Stac... candidate being developed for the treatment,of ac...polar disorder.,Alexza believes the novel, non-inv...ties resulting from inhaled loxapine administratio...
(Date:7/24/2008).../ -- Headlines claiming "soy,products lower sperm ...e,preliminary study that Dr. Jorge Chavarro, publ...collected intake of soyfoods and not on,specific d...d by many,issues, thus I feel the results should b... Tammy Hedlund, a researcher in prostate cancer,pr...
(Date:7/24/2008)... body temperature, for home,and clinical use, WES...-Med, Inc.,(subsidiary of American Scientific Reso...ibutor of the Thermofocus(R) 5-in-1 non-contact,th... clinical study,conducted by the Second Children,s...y, which proves that the Thermofocus(R) measures b...
(Date:7/24/2008)...ire-FirstCall/ -- NicOx S.A.,(Euronext Paris: COX)...week,open label safety extension that was conducte...y for naproxcinod. The results revealed no unexpec...r the one-year duration of,the study, as measured ...ion, the results showed that the patients, mean bl...
Breaking Medicine Technology:Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 2Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 3Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 4Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 5Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 6Soyfoods Do Not Impact Sperm Count 2Pediatric Study Finds 21st Century Non-Contact Thermometer as Accurate as Conventional Thermometers 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 3NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 4Armed beetles find a mate whatever their size 2646 1Small Business Health Care Survey Points to Need for Reform 15325 1Small Business Health Care Survey Points to Need for Reform 15325 2Clarient to Present at the B Riley 26 Co 9th Annual Las Vegas Investor Conference 15320 1Clarient to Present at the B Riley 26 Co 9th Annual Las Vegas Investor Conference 15320 2Patient Experience Expert to Present The Power of Wow 21 in Health Care Service Delivery 4227 1Patient Experience Expert to Present The Power of Wow 21 in Health Care Service Delivery 4227 2
...PRNewswire/ -- Asenapine -- an,investigational dru... business unit of Akzo Nobel, for bipolar I disord...e effective than placebo,in treating acute manic a...er, according to new Phase III results, from a stu...on,s 2007 Annual,Meeting. , In the three-week stud...
...ent Reduction in Risk of Hospitalization,from Croh...Ill., May 22, 2007 /PRNewswire-FirstCall/ -- Abbot... of a pivotal study,presented at the Digestive Dis...ng patients with moderate to severely active,Crohn...ntenance,therapy were almost 60 percent less likel...
Other Medicine Technology:Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 2Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 3Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 4New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 2New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 3New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 4New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 5New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 6New Analysis of Data Shows Treatment With Abbott's Humira,(Adalimumab) Significantly Reduced Disease-Related Hospitalization,for Patients with Crohn's Disease 7
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
Medicine Products: